

Major R&D Pipeline: 3ADCs

Phase 1		Phase 2	Phase 3	Filed
(US/EU/Asia) HER2+ BC 2L~/1L DESTINY-Breast07	(JP/US) NSCLC, TNBC, HR+ BC, SCLC, urothelial, GC, esophageal, etc. TROPION-PanTumor01	(US/EU/Asia) TNBC (durvalumab combo) BEGONIA	(JP/US/EU/Asia) HER2+ BC 3L DESTINY-Breast02	(JP/US/EU/Asia) HER2+ BC 2L DESTINY-Breast03
(US/EU/Asia) HER2 low BC Chemo naïve/ post chemo DESTINY-Breast08	(CN) NSCLC, TNBC TROPION-PanTumor02	(CN) HER2+ GC 3L DESTINY-Gastric06	(JP/US/EU/Asia) HER2+ BC post neoadjuvant DESTINY-Breast05	(EU) HER2+ GC 2L DESTINY-Gastric02
(JP/US/EU/Asia) HER2+ GC combo, 2L~/1L DESTINY-Gastric03	(JP/US/EU/Asia) NSCLC (w/o actionable mutation, pembrolizumab combo) TROPION-Lung02	(JP/US/EU) HER2+ NSCLC 2L~ DESTINY-Lung01	(JP/US/EU/Asia) HER2 low BC chemo naïve DESTINY-Breast06	(US) HER2 mutated NSCLC 2L~ DESTINY-Lung01
(EU/Asia) HER2+ NSCLC (durvalumab combo) 1L DESTINY-Lung03	(JP/US/EU) NSCLC (w/o actionable mutation, durvalumab combo) TROPION-Lung04	(JP/US/EU/Asia) HER2 mutated NSCLC 2L~ DESTINY-Lung02	(JP/US/EU/Asia) HER2+ BC 1L DESTINY-Breast09	(JP/US/EU/Asia) HER2 low BC post chemo DESTINY-Breast04
(US/EU) BC, bladder (nivolumab combo)	(US/EU/Asia) TNBC (durvalumab combo) BEGONIA	(CN) HER2 mutated NSCLC 2L~ DESTINY-Lung05	(JP/US/EU/Asia) HER2+ BC neoadjuvant DESTINY-Breast11	
(US/EU) BC, NSCLC (pembrolizumab combo)	(JP/US/EU/Asia) solid tumors (AZD5305 combo) PETRA	(US/EU/Asia) NSCLC (durvalumab combo) 2L~ HUDSON	(JP/US/Asia) HER2+ GC 2L DESTINY-Gastric04	
(US/EU/Asia) solid tumors (AZD5305 combo) PETRA	(JP/US/EU/Asia) NSCLC	(JP/US/EU) HER2+ CRC 3L DESTINY-CRC01	(JP/US/EU/Asia) NSCLC 1L (w/ exon 19 or exon 20 mutation) DESTINY-Lung04	
	(JP/US) EGFR mutated NSCLC (osimertinib combo)	(JP/US/EU/Asia) HER2+ CRC 3L DESTINY-CRC02	(JP/US/EU/Asia) NSCLC 2/3L TROPION-Lung01	
	(JP/US) HER3+ BC	(JP/US/EU/Asia) HER2 mutated tumor DESTINY-PanTumor01	(JP/US/EU/Asia) NSCLC (w/o actionable mutation, pembro combo) 1L TROPION-Lung08	
		(US/EU/Asia) HER2 expressing tumor DESTINY-PanTumor02	(JP/US/EU/Asia) HR+ BC 2/3L TROPION-Breast01	
		(JP/US/EU/Asia) NSCLC (w/ actionable mutation) TROPION-Lung05	(JP/US/EU/Asia) TNBC 1L TROPION-Breast02	
		(JP/US/EU/Asia) EGFR mutated NSCLC 2L ORCHARD	(JP/US/EU/Asia) EGFR mutated NSCLC 2L HERTHENA-Lung02	
		(JP/US/EU/Asia) EGFR mutated NSCLC 3L HERTHENA-Lung01		

- T-DXd
- Dato-DXd
- HER3-DXd

project in oncology that is planned to be submitted for approval in some countries/regions based on the results of phase 2 trials

Breakthrough Designation (US)

BC: breast cancer, CRC: colorectal cancer, GC: gastric cancer, NSCLC: non-small cell lung cancer, SCLC: small cell lung cancer, TNBC: triple negative breast cancer

Major R&D Pipeline: Alpha

Phase 1		Phase 2		Phase 3		Filed	
DS-7300 (JP/US) B7-H3-directed ADC ESCC, CRPC, squamous NSCLC, etc.	PLX2853 (US) BET inhibitor AML	Valemetostat (DS-3201) (JP/US/EU/Asia) EZH1/2 inhibitor PTCL		Pexidartinib (JP/Asia) CSF-1/KIT/FLT3 inhibitor Tenosynovial giant cell tumor		Valemetostat (DS-3201) (JP) EZH1/2 inhibitor ATL/L	
DS-6000 (US) CDH6-directed ADC Renal cell carcinoma, ovarian cancer	PLX2853 (US) BET inhibitor Solid tumor	Valemetostat (DS-3201) (EU) EZH1/2 inhibitor BCL		Quizartinib (JP/US/EU/Asia) FLT3 inhibitor AML 1L		VN-0107/MEDI3250 (JP) Live attenuated influenza vaccine nasal spray	
DS-1055 (JP/US) Anti-GARP antibody Solid tumors	PLX2853 (US) BET inhibitor Gynecologic neoplasms, ovarian cancer	DS-1001 (JP) Mutant IDH1 inhibitor Glioma		Esaxerenone (JP) MR blocker Diabetic nephropathy			
DS-1211 (US) TNAP inhibitor Pseudoxanthoma elasticum	PLX2853 (US) BET inhibitor Prostate cancer	DS-7300 (JP/US/EU/Asia) B7-H3-directed ADC SCLC		VN-0102/JVC-001 (JP) Measles mumps rubella combined vaccine			
DS-6016 (JP) Anti-ALK2 antibody Fibrodysplasia ossificans progressiva	DS-1594 (US) Menin-MLL binding inhibitor AML, ALL	DS-5141 (JP) ENA oligonucleotide DMD		DS-5670 (JP) COVID-19 mRNA vaccine COVID-19 (booster vaccination)			
DS-7011 (US) Anti-TLR7 antibody Systemic lupus erythematosus	DS-9606 (US/EU) Target non-disclosure ADC Solid tumors	DS-5670 (JP) COVID-19 mRNA vaccine COVID-19 (initial vaccination)					
DS-2325 (US) KLK5 inhibitor Netherton syndrome	VN-0200 (JP) RS virus vaccine RS virus infection						

- Oncology
- Specialty medicine
- Vaccine

project in oncology that is planned to be submitted for approval in some countries/regions based on the results of phase 2 trials

★ SAKIGAKE Designation (JP) ★ Orphan drug designation (JP/US/EU)

ALL: acute lymphoblastic leukemia, AML: acute myeloid leukemia, ATL/L: adult T-cell leukemia/lymphoma, BCL: B cell lymphoma, CRPC: castration-resistant prostate cancer, DMD: Duchenne muscular dystrophy, ESCC: esophageal squamous cell carcinoma, FOP: Fibrodysplasia ossificans progressiva, LBCL: large B cell lymphoma, NSCLC: non small cell lung cancer, SCLC: small cell lung cancer, PTCL: peripheral T-cell lymphoma